Matuzumab
From Wikipedia, the free encyclopedia
|
Matuzumab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Human |
| Target | EGFR |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to EGFR (epidermal growth factor receptor) with high affinity.
Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it is currently undergoing phase II clinical trials for the treatment of colorectal, lung and stomach cancer. On August 29, 2007, Merck Serono announced that the preliminary results of the colorectal cancer study were less than promising, and that further trials for treating this type of cancer may be abandoned. The results of the lung and stomach cancer studies are expected in 2008.[1]
[edit] Footnotes
- ^ Krebsmedikament floppt. n-tv, August 29, 2007. [Article in Gemran]. Retrieved 2007-AUG-27.
[edit] External links
|
|||||||||||||||||||||||
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
